Follow Us      

LOGIN
 
Share Page:
Back

Volume 37 , Issue 6
November/December 2017

Pages e321e327


Maxillary Sinus Elevation Surgery with ChronOS and Autogenous Bone Graft: Immunohistochemical Assessment of RUNX2, VEGF, TRAP, and Osteocalcin


Rodrigo dos Santos Pereira, DDS, MSc, PhD/Fernanda Brasil Jorge Daura Boos, DDS, MSc, PhD/Luis Fernado Gorla, DDS/Idelmo Rangel Garcia Jr, DDS, MSc, PhD/Roberta Okamoto, DDS, MSc, PhD/Eduardo Hochuli-Vieira, DDS, MSc, PhD


PMID: 28834531
DOI: 10.11607/prd.2606

The purpose of this study was to evaluate a composite graft of ChronOS, a betatricalcium phosphate (β-TCP), mixed 1:1 with an autogenous bone graft in human maxillary sinus augmentation. A total of 12 maxillary sinuses were grafted with an autogenous bone graft (control group), and 9 maxillary sinuses were grafted with ChronOS mixed 1:1 with an autogenous bone graft (test group). After 6 months, biopsy samples were obtained concurrent to the placement of dental implants and were subjected to histomorphometric and immunohistochemical analyses for Runt-related transcription factor 2 (RUNX2), vascular endothelial growth factor (VEGF), tartrate-resistant acid phosphatase, and osteocalcin. Histologic analysis of samples obtained from the test group revealed the presence of immature bone, while samples from the control group indicated lamellar bone formation. However, both types of bone grafts were well vascularized. The new bone formation averaged 25.4% 6.4% in the test group and 38.6% 10.5% in the control group (P = .001). Immunostaining of samples in the test group showed high cellular turnover. The outcomes of this study demonstrate a delay in bone formation but intense cellular differentiation after 6 months of bone graft healing in the test group. The amount of immature bone and the immunostaining for RUNX2 and VEGF provide evidence of an osteogenic pathway that can improve the bone formation rate.


Full Text PDF File | Order Article

 

 
Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.

 

© 2017 Quintessence Publishing Co, Inc

PRD Home
Current Issue
Ahead of Print
Archive
Author Guidelines
About
Accepted Manuscripts
Submission Form
Submit
Reprints
Permission
Advertising
Quintessence Home
Terms of Use
Privacy Policy
About Us
Contact Us
Help